Akebia Therapeutics
AKBA
177 hedge funds and large institutions have $338M invested in Akebia Therapeutics in 2025 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 66 increasing their positions, 40 reducing their positions, and 18 closing their positions.
122% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 18
75% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $1.21M
65% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 40
13% more funds holding
Funds holding: 157 → 177 (+20)
5.42% more ownership
Funds ownership: 41.23% → 46.64% (+5.4%)
14% less capital invested
Capital invested by funds: $394M → $338M (-$56.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.71M |
| 4 |
Citigroup
New York
|
+$5.93M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.23M |
| 2 |
Goldman Sachs
New York
|
-$7.21M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$5.29M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.64M |
| 5 |
Morgan Stanley
New York
|
-$3.41M |
AKBA Hedge Fund Activity: Q3 2025 in Review
177 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2025, worth a combined $338M — down 14% from $394M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new AKBA positions and 18 closed out — a net gain of 22 holders — while 66 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $12.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $7.23M sold.
- 177 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2025, up from 157 in Q2 2025.
- Funds reported $338M of Akebia Therapeutics stock for Q3 2025, down 14% quarter-over-quarter.
- 40 funds opened new Akebia Therapeutics positions in Q3 2025 and 18 closed out, a net change of +22 holders.
- The largest Akebia Therapeutics buyer in Q3 2025 was State Street, an estimated $12.8M added.
- The largest Akebia Therapeutics seller in Q3 2025 was Great Point Partners, an estimated $7.23M sold.
Based on aggregated 13F filings for Q3 2025.